Abstract
G protein-coupled receptors (GPCRs) can utilize receptor tyrosine kinases (RTKs) to mediate important cellular responses such as proliferation, differentiation and survival. Recent advances in the field suggest that GPCRinduced transactivation of RTKs might be important for diseases such as cancer and cardiac hypertrophy. Depending on the receptor and cell type, GPCR signaling involves activation of several different RTKs. By activating different subsets of RTKs, GPCRs can fine-tune their effects on target cells. Furthermore, RTK-independent signaling pathways also initiated by GPCRs may modify the biological read out of the transactivated RTKs. This review focuses on the mechanisms how GPCRs and intracellular messengers elicit transactivation of different RTKs and the resulting different biological responses.
Keywords: transactivation, map kinases, cell survival, egf receptor, pdgf receptor, trk, akt
Current Pharmaceutical Design
Title: Receptor Tyrosine Kinases are Signaling Intermediates of G Protein- Coupled Receptors
Volume: 10 Issue: 28
Author(s): A. Piiper and S. Zeuzem
Affiliation:
Keywords: transactivation, map kinases, cell survival, egf receptor, pdgf receptor, trk, akt
Abstract: G protein-coupled receptors (GPCRs) can utilize receptor tyrosine kinases (RTKs) to mediate important cellular responses such as proliferation, differentiation and survival. Recent advances in the field suggest that GPCRinduced transactivation of RTKs might be important for diseases such as cancer and cardiac hypertrophy. Depending on the receptor and cell type, GPCR signaling involves activation of several different RTKs. By activating different subsets of RTKs, GPCRs can fine-tune their effects on target cells. Furthermore, RTK-independent signaling pathways also initiated by GPCRs may modify the biological read out of the transactivated RTKs. This review focuses on the mechanisms how GPCRs and intracellular messengers elicit transactivation of different RTKs and the resulting different biological responses.
Export Options
About this article
Cite this article as:
Piiper A. and Zeuzem S., Receptor Tyrosine Kinases are Signaling Intermediates of G Protein- Coupled Receptors, Current Pharmaceutical Design 2004; 10 (28) . https://dx.doi.org/10.2174/1381612043382936
DOI https://dx.doi.org/10.2174/1381612043382936 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Can PET Imaging Facilitate Optimization of Cancer Therapies?
Current Pharmaceutical Design Interlinking of Hypoxia and Estrogen in Thyroid Cancer Progression
Current Medicinal Chemistry Synthesis of Silica Based Nanoparticles Against the Proliferation of Human Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Antibody-Targeted RNase Fusion Proteins (ImmunoRNases) for Cancer Therapy
Current Pharmaceutical Biotechnology Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases
Current Neuropharmacology Therapeutic Targeting of Developmental Signaling Pathways in Medulloblastoma: Hedgehog, Notch, Wnt and Myc
Current Signal Transduction Therapy Ultrasound-Triggered Immunotherapy for Cancer Treatment: An Update
Current Protein & Peptide Science Patent Selections
Recent Patents on Biotechnology Targeting CSC-Related miRNAs for Cancer Therapy by Natural Agents
Current Drug Targets Treatment of Anaplastic Thyroid Cancer: Is there a Role for PPARγ Agonists?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Treatment of Diffuse-Type Gastric Cancer Cells Using 213Bi-Radioimmunoconjugates In Vitro and In Vivo Following Intraperitoneal Dissemination
Current Radiopharmaceuticals Potassium Channels are a New Target Field in Anticancer Drug Design
Recent Patents on Anti-Cancer Drug Discovery Recent Advances in the Development of MMPIs and APNIs Based on the Pyrrolidine Platforms
Mini-Reviews in Medicinal Chemistry Taming Oncogenic Signaling at Protein Interfaces: Challenges and Opportunities
Current Topics in Medicinal Chemistry MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry Inhibition of HIV-1 Replication by RNA-Based Strategies
Current HIV Research Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry Restoring p53 Function in Cancer: Novel Therapeutic Approaches for Applying the Brakes to Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery New N’-Arylidene-2-[(4-Nitrophenyl)Piperazın-1-yl]Acetohydrazide Derivatives: Synthesis and Anticancer Activity Investigation
Letters in Drug Design & Discovery